Selegiline Hydrochloride NDC 71335-2676

NDC codes

FDA NDC Directory

Product NDC (as listed)71335-2676Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71335-2676Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
71335-2676-1	71335267601	30 CAPSULE in 1 BOTTLE (71335-2676-1)Marketed from Aug 18, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Selegiline Hydrochloride
Generic name (nonproprietary): selegiline hydrochloride
Active ingredients: Selegiline hydrochloride — 5 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Bryant Ranch Prepack
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 075352
Marketing start: Apr 1, 2021
Listing expires: Dec 31, 2026
Other FDA classes: Monoamine Oxidase Inhibitors (Mechanism)Monoamine Oxidase-B Inhibitors (Mechanism)
Identifiers: Product ID 71335-2676_c3d9a9b2-d6f7-4008-9fa8-e198f1f5bbbbSPL ID c3d9a9b2-d6f7-4008-9fa8-e198f1f5bbbbSPL set ID b8eb0a00-adc7-4aaf-987c-fa1b207b2996RxCUI 859186UNII 6W731X367Q
Pharmacologic class: Monoamine Oxidase Inhibitor; Monoamine Oxidase Type B Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N471335267601 followed by a unit qualifier and the quantity

Package 71335-2676-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 18, 2025.

Indications (excerpt from the label)

INDICATIONS & USAGE Selegiline hydrochloride capsules, USP are indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy. Evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. Selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily l…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 075352

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 075352
Product	Strength	Form · route	Labeler	Product NDC
Selegiline Hydrochloride	Selegiline hydrochloride 5 mg/1	CapsuleOral	Marlex Pharmaceuticals, Inc.	10135-737
Selegiline Hydrochloride	Selegiline hydrochloride 5 mg/1	CapsuleOral	Novitium Pharma LLC	70954-504